Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement ...

The iron chelator deferoxamine has shown some potential as an antitumor agent in a small number of patients with hepatocellular carcinoma who did not have a response to other agents.

DESFERAL® is now marketed in over 60 countries. It is manufactured in Europe. Its injectable (subcutaneous) formulation offers a well-known safety profile and extensive experience in medical ...

Subcutaneous infusion of DFO is the standard for iron chelation, particularly as initial therapy for cardiac iron overload from blood transfusion.

Thalassemia is a genetic disorder characterized by reduced or absent synthesis of the beta chains of hemoglobin, leading to ...

The iron chelator deferoxamine has shown some potential as an antitumor agent in a small number of patients with hepatocellular carcinoma who did not have a response to other agents.

Question In patients with myelodysplasia who have severe anemia requiring long-term transfusion therapy, is there any documented evidence that rapid (30-60 min) infusion of deferoxamine at time of ...

Compared with oral administration, continuous subcutaneous infusion of carbidopa/levodopa was linked to nearly 2 more hours of “on” time without dyskinesia in adults with Parkinson’s disease ...

Public sector hospitals in India face a critical shortage of Desferal, a vital iron chelator, endangering thalassemia patients who cannot afford its high cost.

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection ...